EAGLE PHARMACEUTICALS, INC.: Nasdaq/NYSE listing notice — Eagle Pharma receives Nasdaq deficiency notice for delayed Q3 10-Q filing

EAGLE PHARMACEUTICALS, INC.

Nasdaq notified Eagle on Nov 27, 2023 of non-compliance with Rule 5250(c)(1) due to late Q3 10-Q.
Company has until Jan 26, 2024 to submit a compliance plan; if accepted, Nasdaq may extend to May 7, 2024.
Failure to regain compliance could lead to delisting; hearing may be requested but no assurance of success.
No financial impact disclosed; risk of trading suspension or delisting if plan not accepted or filing not made.

item 3.01 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

EAGLE PHARMACEUTICALS, INC. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: late filing
Rules: 5250(c)(1)

Exact text from the filing

rom the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that due to the delay in filing the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 (the “Form 10-Q”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Rule”), which requires listed companies to timely file all periodic financial reports with the Securities and Exchange Commission (the “SEC”). The Notice provides that the Company has 60 calendar days from the date of the Notice, or until January 26, 2024, to submit to Nasdaq a plan

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001104659-23-121848

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.